Bond Avillion 2 Development

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Bond Avillion 2 Development sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials none currently recruiting 6 completed later-stage tilt upper quartile by trial count

Bond Avillion 2 Development: 6 sponsored US clinical trials, none currently recruiting.

Bond Avillion 2 Development sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 4 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Asthma, with 1 trials.

Upper-quartile sponsor footprint

Bond Avillion 2 Development sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

6 total, page 1 of 1

COMPLETED Phase 3

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

NCT05505734
COMPLETED Phase 1

To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.

NCT04848662
COMPLETED Phase 3

A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma

NCT04234464
COMPLETED Phase 3

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma

NCT03847896
COMPLETED Phase 3

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

NCT03769090
COMPLETED Phase 2

A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis

NCT03384745

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 3 4

Therapeutic Areas

Asthma 1

How the Bond Avillion 2 Development archive is shaped

6 indexed studies, none listed as recruiting (0% open); 6 completed (100%).

Phase mix: 4 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Asthma (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Bond Avillion 2 Development: archived-pipeline peers nationwide

Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Bond Avillion 2 Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share Bond Avillion 2 Development23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan Branch10xBio22nd Century Group3-C Institute for Social Development3 Waves Wellness
Bond Avillion 2 Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Bond Avillion 2 Development sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Bond Avillion 2 Development page

6 registered trials is a research-attention snapshot, not an endorsement of Bond Avillion 2 Development or any single study.

  • None of Bond Avillion 2 Development's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Asthma is the condition Bond Avillion 2 Development studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Asthma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Bond Avillion 2 Development pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.